Back to Agenda
Session 3: Point to Consider on CMC Comparability Challenges Through the Development of the Gene Therapy Products [Japanese and English]
Session Chair(s)
Kazunobu Oyama, PHD
CMC Regulatory Affairs, Director
Daiichi Sankyo Company, Limited, Japan
Mika Yoshimatsu
Head of CMC Development
T Cell Nouveau Inc., Japan
Speaker(s)
Jaclyn Moxham
Pfizer , United States
Niamh M Kinsella, PHD
NDA Group, United Kingdom
Principal Consultant
Alison Armstrong
Merck BioReliance, United Kingdom
Global Head of Field Technology Management
Have an account?